Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following significant stock losses due to disappointing clinical trial results for its lead drug candidate, ersodetug [2][4]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker RZLT [2]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [4]. Group 2: Clinical Trial Results - On December 11, 2025, Rezolute's shares experienced a sharp decline as the results from the Phase 3 sunRIZE clinical trial were released [4]. - The trial failed to meet both primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [4]. Group 3: Legal Implications - Investors who suffered significant losses in Rezolute stock or options are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant drop in its stock price due to disappointing clinical trial results for its lead drug candidate, ersodetug [4][5]. Group 1: Company Overview - Rezolute, Inc. is a publicly traded company listed on NASDAQ under the ticker RZLT [4]. - The company focuses on developing treatments for congenital hyperinsulinism, with ersodetug being its lead drug candidate [5]. Group 2: Recent Developments - On December 11, 2025, Rezolute's shares experienced a dramatic decline, falling from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [6]. - The decline was triggered by the failure of the Phase 3 sunRIZE clinical trial for ersodetug, which did not meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events compared to placebo [5]. Group 3: Legal Implications - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to discuss their legal rights [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Insights - Rezolute, Inc. reported financial results and business updates for the three months ended December 31, 2025, focusing on its late-stage rare disease treatment for hypoglycemia caused by hyperinsulinism [1] Financial Performance - Cash, cash equivalents, and investments in marketable securities were $132.9 million as of December 31, 2025, down from $167.9 million as of June 30, 2025 [7] - Research and development (R&D) expenses increased to $14.3 million for the second quarter of fiscal 2026, compared to $12.6 million for the same period a year ago, primarily due to increased clinical trial activities and higher employee-related expenses [8] - General and administrative (G&A) expenses rose to $9.9 million for the second quarter of fiscal 2026, up from $4.5 million for the same period a year ago, attributed to increased professional fees and employee-related expenses [9] - The net loss for the second quarter of fiscal 2026 was $22.8 million, compared to a net loss of $15.7 million for the same period a year ago [9] Clinical Development - The Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism did not meet its primary or key secondary endpoints, although reductions in hypoglycemia events were observed [6] - The ongoing upLIFT study for tumor hyperinsulinism is currently enrolling participants, with topline results expected in the second half of 2026 [6] - In January 2026, data from the Expanded Access Program indicated that 75% of tumor HI patients achieved complete discontinuation of IV dextrose/TPN, supporting the efficacy of ersodetug [6] Corporate Updates - Rezolute plans to meet with the FDA under Breakthrough Therapy Designation to discuss next steps for the ersodetug program following the sunRIZE study results [6] - A virtual Investor Event in November 2025 highlighted the commercial opportunities for ersodetug, featuring insights from leading physician experts on the unmet clinical need in hyperinsulinism [6]

Company Overview - Rezolute, Inc. is a company listed on NASDAQ under the ticker symbol RZLT [2] - The company is currently facing legal scrutiny due to significant stock losses experienced by investors [2][3] Recent Developments - On December 11, 2025, Rezolute's shares experienced a dramatic decline, dropping approximately 85-90% from a previous close of around $10.94 to an intraday low of approximately $0.90 [4][5] - This sharp decline was triggered by disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, which failed to meet both primary and key secondary endpoints [4] Clinical Trial Results - The Phase 3 clinical trial for ersodetug aimed at treating congenital hyperinsulinism did not show statistically significant reductions in hypoglycemia events compared to placebo [4]

Core Insights - Rezolute, Inc. is under investigation by Faruqi & Faruqi, LLP due to significant stock losses following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug [2][3]. Group 1: Company Performance - Rezolute's shares experienced a dramatic decline on December 11, 2025, dropping from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decrease [3][4]. - The Phase 3 sunRIZE clinical trial for ersodetug did not meet its primary and key secondary endpoints, with the highest dose showing non-significant reductions in hypoglycemia events compared to placebo [3]. Group 2: Legal and Investor Actions - Faruqi & Faruqi, LLP is encouraging investors who suffered significant losses in Rezolute stock or options to contact them to discuss potential legal options [1]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2].

Company Overview - Rezolute, Inc. is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI) [3] - The company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and real-world cases for both congenital and tumor HI [3] Upcoming Events - Management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place on February 11-12, 2026, in New York [1] - One-on-one investor meetings will be held throughout the conference, and interested investors can contact their Guggenheim representative to schedule a meeting with the management team [2]

Group 1 - Rezolute, Inc. shares experienced a significant decline on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug, which is intended for treating congenital hyperinsulinism [5] - The clinical trial failed to meet both its primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [5] - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. for investors who suffered significant losses [2][4]

Core Viewpoint - Rezolute, Inc. is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [1][2]. Group 1: Study Results - The Phase 3 sunRIZE study did not meet its primary endpoint, as results were "not statistically significant" compared to the placebo group, which showed a 40% improvement [2]. - The study also failed to meet its key secondary endpoint, which was similarly "not statistically significant" compared to the placebo [2]. - Management expressed disappointment and stated they are conducting a thorough evaluation to understand the study outcomes better [2]. Group 2: Stock Market Reaction - Following the announcement of the study results, Rezolute's stock price plummeted over 89%, opening at $1.21 per share [2].

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following significant losses in its stock [2][4] - Rezolute's shares experienced a sharp decline on December 11, 2025, due to disappointing topline results from its Phase 3 sunRIZE clinical trial for the drug candidate ersodetug [5] - The clinical trial failed to meet both primary and key secondary endpoints, with the highest dose showing reductions in hypoglycemia events that were not statistically significant compared to placebo [5] Group 2 - Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4] - The firm encourages investors who suffered losses in Rezolute stock or options to discuss their legal rights directly with their attorneys [1]

Core Viewpoint - Rezolute, Inc. is under investigation for potential violations of federal securities laws following the announcement of disappointing results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [1][2]. Group 1: Study Results - The Phase 3 sunRIZE study did not meet its primary endpoint, as results were "not statistically significant" compared to the placebo group, which showed a 40% improvement [2]. - The study also failed to meet its key secondary endpoint, which was similarly "not statistically significant" compared to the placebo [2]. - Management expressed disappointment and stated they are conducting a thorough evaluation to understand the study outcomes better [2]. Group 2: Stock Performance - Following the announcement of the study results, Rezolute's stock price plummeted over 89%, opening at $1.21 per share [2].